Research and Practice in Thrombosis and Haemostasis

Article	Citations
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis	350
A proposal for staging COVID‐19 coagulopathy	76
Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis	73
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality	65
Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials	63
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)	58
Using heparin molecules to manage COVID‐2019	55
Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis	53
Sexism in the management of bleeding disorders	51
Tranexamic acid evidence and controversies: An illustrated review	50
Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome	48
Thrombosis and coagulopathy in COVID‐19: An illustrated review	46
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients	45
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study	41
Comparison of the coagulopathies associated with COVID‐19 and sepsis	39
Potential role of platelets in COVID‐19: Implications for thrombosis	39
Emergence of institutional antithrombotic protocols for coronavirus 2019	39
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis	38
Hematologic concerns in extracorporeal membrane oxygenation	36
Posters Abstracts	36
Abstract	36
Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review	36
Abstracts	34
Anticoagulation practice patterns in COVID‐19: A global survey	34
Essential aspects of the follow‐up after acute pulmonary embolism: An illustrated review	33

Protease‐activated receptors: An illustrated review	31
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19	31
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)	29
The role of platelets in sepsis	29
The contact activation system as a potential therapeutic target in patients with COVID‐19	28
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries	28
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features	28
The psychological impact of pulmonary embolism: A mixed‐methods study	25
Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital	25
COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance	24
Hormonal therapies and venous thrombosis: Considerations for prevention and management	24
Blood clot contraction: Mechanisms, pathophysiology, and disease	24
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE	24
The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease	23
Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer	22
COVID‐19 hypothesis: Activated protein C for therapy of virus‐induced pathologic thromboinflammation	22
Visualizing thrombosis to improve thrombus resolution	22
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment	21
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants	21
Impact of novel hemophilia therapies around the world	20
Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management	20
Venous thromboembolism in multiple myeloma is associated with increased mortality	19
Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committ	19
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set	19
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation	19
Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting	19
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease	18
Gender gap in women authors is not worse during COVID‐19 pandemic: Results from Research and Practice in Thrombosis and Haemostasis	18
Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system	18
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors	18
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial	18
Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis	17
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts	17
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate	17
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)	17
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma	17
Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants	17
Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial	17
A call to action for anticoagulation stewardship	16
Viscoelastic testing: an illustrated review of technology and clinical applications	16
Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting	15
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern	15
Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease	15
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report	15
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?	15
An illustrated review of bleeding assessment tools and common coagulation tests	14
Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients	14
Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination	14
A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score	14
Caging the dragon: Research approach to COVID‐19–related thrombosis	14

Hemophilia gene therapy knowledge and perceptions: Results of an international survey	14
High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies	14
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status	14
DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples	14
Platelets in the neonate: Not just a small adult	14
Direct oral anticoagulants for unusual‐site venous thromboembolism	14
Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia	13
ST Genesia reference values of 117 healthy donors measured with STG‐BleedScreen, STG‐DrugScreen and STG‐ThromboScreen reagents	13
Thrombotic microangiopathies: An illustrated review	13
Core and shell platelets of a thrombus: A new microfluidic assay to study mechanics and biochemistry	13
The intersection of vector biology, gene therapy, and hemophilia	13
COVID‐19 and venous thromboembolism: A narrative review	13
Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism	13
Physical forces regulating hemostasis and thrombosis: Vessels, cells, and molecules in illustrated review	13
Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors	12
Hemostasis and fibrinolysis in COVID‐19 survivors 6 months after intensive care unit discharge	12
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding	12
MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia	12
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method	12
Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay	12
Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019	11
The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description	11
The ongoing enigma of SARS‐CoV‐2 and platelet interaction	11
Patient selection for hemophilia gene therapy: Real‐life data from a single center	11
The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19	11
Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation	11
Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia	11
GPIbα is the driving force of hepatic thrombopoietin generation	11
Respective roles of Glycoprotein VI and FcγRIIA in the regulation of αIIbβ3‐mediated platelet activation to fibrinogen, thrombus buildup, and stability	11
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing	11
Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity	11
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies	10
Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research	10
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review	10
Racial differences in protein S Tokushima and two protein C variants as genetic risk factors for venous thromboembolism	10
Antiviral anticoagulation	10
Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology	10
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban	10
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study	10
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study	10
Pulmonary embolism and deep vein thrombosis—comorbidities and temporary provoking factors in a register‐based study of 1.48 million people	10
Inhibition of platelet adhesion, thrombus formation, and fibrin formation by a potent αIIbβ3 integrin inhibitor from ticks	10
Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records	10
Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis	10
Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vaso‐occlusive crisis	10
Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay	10
Building a better NET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders	10
Fibrinolysis: an illustrated review	10
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report	10
Development of inhibitors in hemophilia A: An illustrated review	10
Venous thromboembolism after lower extremity orthopedic surgery: A population‐based nationwide cohort study	10
Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population	10
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination	9
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy	9
D‐dimer testing in clinical practice in the era of COVID‐19	9
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study	9
Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation	9
Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura	9
2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines	9
Liver fibrosis is driven by protease‐activated receptor‐1 expressed by hepatic stellate cells in experimental chronic liver injury	9
Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples	9
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety	9
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients	9
The lived experience of women with a bleeding disorder: A systematic review	9
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study	9
D‐dimer, thrombin generation, and risk of a first venous thrombosis in the elderly	9
Menstruation, anticoagulation, and contraception: VTE and uterine bleeding	9
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial	9
Optimization of DOAC management services in a centralized anticoagulation clinic	9
Reproductive issues in women on direct oral anticoagulants	9
Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications	8
Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia	8
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial	8
Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months	8
Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count	8
Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience	8
Developing and optimizing a computable phenotype for incident venous thromboembolism in a longitudinal cohort of patients with cancer	8
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation	8
Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey	8
Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study	8

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy	8
Platelet CLEC‐2 and lung development	8
Acquired hemophilia following COVID‐19 vaccination: Case report and review of literature	8
Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance	8
Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: Observational study of efficacy and safety for prophylaxis and treatment	8
Aspirin at 120: Retiring, recombining, or repurposing?	8
Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants	8
Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution	8
Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination	8
Global coagulation assays in patients with diabetes mellitus	8
“If I wasn't a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders	8
Disparities in obstetric hemorrhage outcomes	8
Protease: Serpin complexes to assess contact system and intrinsic pathway activation	8
Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples	8
Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais	8
Bleeding risks for uncharacterized platelet function disorders	8
Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies	8
Prostasin and hepatocyte growth factor B in factor VIIa generation: Serine protease knockdowns in zebrafish	7
Thromboprophylaxis for children hospitalized with COVID‐19 and MIS‐C	7
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States	7
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease	7
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition	7
Diversity, equity, and inclusion in publishing: Calling thrombosis and hemostasis journals to action in support of women	7
Annual report on equity, diversity, and inclusion: Research and Practice in Thrombosis and Haemostasis is meeting its goals	7
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis	7
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	7
Disruptive technology and hemophilia care: The multiple impacts of emicizumab	7
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19	7
Measuring beta‐galactose exposure on platelets: Standardization and healthy reference values	7
Hemostatic phenotypes and genetic disorders	7
Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms	7
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste	7
Epidemiology and 3‐year outcomes of combined oral contraceptive–associated distal deep vein thrombosis	7
Blood and Bone: The quarantine chronicles	7
Anticoagulation, immortality, and observations of COVID‐19	7
Sex‐specific aspects of venous thromboembolism: What is new and what is next?	7
Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ)	7
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use	7
ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6	7
Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort	7
Underrepresentation and undertreatment of women in hematology: An unsolved issue	6
A microfluidic method to investigate platelet mechanotransduction under extensional strain	6
The von Willebrand factor – ADAMTS‐13 axis in malaria	6
Fibronectin binding to von Willebrand factor occurs via the A1 domain	6
Phosphatidylinositol 3‐monophosphate: A novel actor in thrombopoiesis and thrombosis	6
MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study	6
Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors	6
Etiology and outcomes: Thrombotic microangiopathies in pregnancy	6
Compression stockings to prevent postthrombotic syndrome: Literature overview and presentation of the CELEST trial	6
Rate zonal centrifugation can partially separate platelets from platelet‐derived vesicles	6
Association between cardiovascular risk factors and venous thromboembolism in the elderly	6
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies	6
Pulmonary embolism in acute lymphoblastic leukemia — An observational study of 1685 patients treated according to the NOPHO ALL2008 protocol	6
Coagulation biomarkers for ischemic stroke	6
Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield	6
Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study	6
Using an electronic medical record patient portal for warfarin self-management: Empowering children and parents	6
Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study	6
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin	6
Anticoagulant drug‐drug interactions: Highlighting the need for antithrombotic stewardship and shared decision making	6
Assessing quality of life after pulmonary embolism: Comparing results from the PEmb‐QoL with semistructured interviews	6
In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype	6
A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study	6
Social determinants of health in pulmonary embolism management and outcome in hospitals: Insights from the United States nationwide inpatient sample	6
eThrombosis: A new risk factor for venous thromboembolism in the pandemic era	6
Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data	6
Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center	6
Interlaboratory variability of activated protein C resistance using the ETP‐based APC resistance assay	6
Clinical significance of subsegmental pulmonary embolism: An ongoing controversy	6
Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis	6
Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study	6
COVID‐19 pandemic perspectives: A scientific silver lining?	6
Risk of thrombosis with thrombocytopenia syndrome after COVID‐19 vaccination prior to the recognition of vaccine‐induced thrombocytopenia and thrombosis: A self‐controlled case series study in England	6
Hemostasis and tumor immunity	6
Fitness enhances psychosocial well‐being and self‐confidence in young men with hemophilia: Results from Project GYM	6
Mechanisms of cancer-associated thrombosis	6
Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019	5
Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter‐related thrombosis	5
Cryo‐EM structures of coagulation factors	5
Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis	5
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study	5
Evaluation of a new bead‐based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma	5
Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial	5
New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial	5
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	5
Heparin-induced thrombocytopenia: An illustrated review	5
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021	5
Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care	5
Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety	5
Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys	5
Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review	5
Complement factor C4a does not activate protease‐activated receptor 1 (PAR1) or PAR4 on human platelets	5
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA	5
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists	5
Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates	5